1-20 of 43
Seung Tae Lee
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B-Cell Non-Hodgkin Lymphomas (NHL)

Sarit Assouline, Katharine L. Lewis, Rosemary Anne Harrup, Robert J Lutz, Jenny Thirlway, Jutta Deckert, David M Browning, Debra L Wood, Paul I. Nadler, Seung Tae Lee
Journal: Blood
Blood (2023) 142 (Supplement 1): 3095.
https://doi.org/10.1182/blood-2023-173955
Published: 2023
Journal Articles

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D Phelan, Da Wei Huang, George Wright, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances A Tosto, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Svetlana Pack, Cody J Peer, Oluwatobi Arisa, Esther Mena, Maria L. Lindenberg, Ethan Bergvall, Craig A. Portell, Rafic J Farah, Seung Tae Lee, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Anna M Juanitez, Crystal Lu, Allison P. Jacob, Heidi Simmons, William D Figg, Seth M. Steinberg, Elaine S Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H Wilson
Journal: Blood
Blood (2023) 142 (Supplement 1): 434.
https://doi.org/10.1182/blood-2023-180173
Published: 2023
Journal Articles

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Nitin Jain, James D'Olimpio, Andew gillis-Smith, Seung Tae Lee, Nirav N. Shah, Javier Pinilla-Ibarz, Catherine C. Coombs, Jacqueline C. Barrientos, Shuo Ma, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 3288.
https://doi.org/10.1182/blood-2023-182568
Published: 2023
Journal Articles

A Subset of Classical Hodgkin Lymphoma Cases Demonstrate CD19 Expression on Hodgkin Reed-Sternberg Cells By Immunohistochemistry

Sarah Helman, Fikru Merechi, Hanan Alharthy, Madhurima Koka, Michael Kallen, Aaron P. Rapoport, Jennie Law, Seung Tae Lee, Zeba N Singh
Journal: Blood
Blood (2023) 142 (Supplement 1): 6125.
https://doi.org/10.1182/blood-2023-174284
Published: 2023
Journal Articles

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

Swami P. Iyer, Sabarish R. Ayyappan, Irl Brian Greenwell, Won Seog Kim, Seung Tae Lee, Jin Seok Kim, Won-Sik Lee, Youngwoo Jeon, William Johnson, Utpal P. Dave, Sung-Soo Yoon, Ka-Won Kang, Florent Carrette, Julien Viotti, A.J. Leyco, Marianna Muller, Steven M. Horwitz
Journal: Blood
Blood (2023) 142 (Supplement 1): 3072.
https://doi.org/10.1182/blood-2023-172537
Published: 2023
Journal Articles

HIV-Associated Lymphoma in an Urban Clinic Population: Epidemiology and Outcomes during the Antiretroviral Therapy Era

Kathryn Kline, Caroline Dunne, Jennie Law, Alonso Heredia, Anthony Devico, Mohammad Sajadi, Ben Atkinson, Seung Tae Lee
Journal: Blood
Blood (2023) 142 (Supplement 1): 3127.
https://doi.org/10.1182/blood-2023-190032
Published: 2023
Journal Articles

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Muhit Ozcan, Fangfang Lv, Lalita Norasetthada, Ewa Paszkiewicz-Kozik, Joaquin Díaz Schmidt, Dipenkumar Modi, Alexander Fosså, Sagun Goyal, Won Seog Kim, Seung Tae Lee, Armando Santoro, Mehmet Sonmez, Kumudu Pathiraja, Nishitha Reddy, Patricia Marinello, Yuqin Song
Journal: Blood
Blood (2023) 142 (Supplement 1): 1720.
https://doi.org/10.1182/blood-2023-186788
Published: 2023
Journal Articles

Real World Experience with a Zuma -1 Cohort 4 Adopted Approach to CRS and Icans in CAR-T Recipients

Chiranjeevi Sainatham, Olga Goloubeva, Philip Margiotta, Hanan Alharthy, Imari Patel, Ali Bukhari, Jennie Law, Seung Tae Lee, Mehmet H. Kocoglu, Jean A. Yared, Nancy M. Hardy, Maggie Nelson, Joseph P McGuirk, Aaron P. Rapoport, Saurabh Dahiya, Forat Lutfi
Journal: Blood
Blood (2023) 142 (Supplement 1): 2122.
https://doi.org/10.1182/blood-2023-183002
Published: 2023
Journal Articles

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J Olszewski, Herbert Eradat, Abraham Avigdor, Netanel A. Horowitz, Sunil Babu, Itai Levi, Matthew McKinney, Seung Tae Lee, Juan Miguel Bergua Burgues, Antonia Rodriguez Izquierdo, Mariana Bastos-Oreiro, Chezi Ganzel, Tae Min Kim, Youngwoo Jeon, Michal Taszner, Mayur Narkhede, Won Seog Kim, Ho-Jin Shin, David Lavie, Dariusz Woszczyk, Diana Dunshee, Amy V. Kapp, Mingzhu Zhou, Connie Lee Batlevi, Wahib Ead, Gila Sellam, Wojciech Jurczak
Journal: Blood
Blood (2023) 142 (Supplement 1): 855.
https://doi.org/10.1182/blood-2023-177588
Published: 2023
Journal Articles

Prognostication of the 2016-Who AML with Myelodysplasia-Related Changes Subclass and Mutations in MDS-Related Genes Using the 2022 European Leukemianet Risk Classification: A Retrospective Study

Fahad Alkaabba, Matthew Williams, Elizabeth Corley, Hanan Alharthy, Kathryn A.F. Kline, Seung Tae Lee, Michael Kallen, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, Moaath K. Mustafa Ali
Journal: Blood
Blood (2022) 140 (Supplement 1): 3237–3238.
https://doi.org/10.1182/blood-2022-170531
Published: 2022
Journal Articles

Efficacy and Safety of Retreatment with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or CD30-Expressing Peripheral T Cell Lymphoma

Dahlia Sano, Sairah Ahmed, Jingmin Liu, Scott Knowles, Seung Tae Lee
Journal: Blood
Blood (2022) 140 (Supplement 1): 12003–12004.
https://doi.org/10.1182/blood-2022-158225
Published: 2022
Journal Articles

Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study

Hanan Alharthy, Fahad Alkaabba, Matthew Williams, Elizabeth Corley, Kathryn A.F. Kline, Jennie Y. Law, Seung Tae Lee, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, Moaath K. Mustafa Ali
Journal: Blood
Blood (2022) 140 (Supplement 1): 9025–9026.
https://doi.org/10.1182/blood-2022-170688
Published: 2022
Journal Articles

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Rafic J. Farah, Seung Tae Lee, Amynah Pradhan, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2022) 140 (Supplement 1): 2289–2291.
https://doi.org/10.1182/blood-2022-167887
Published: 2022
Journal Articles

Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy

Saurabh Dahiya, Tim Luetkens, Stephanie Avila, Saurabh Dahiya, Philip Margiotta, Kim Hankey, Patricia Lesho, Sherri Bauman, Nancy Smith, Kathleen Ruehle, Seung-Tae Lee, Jennie Y. Law, John Baddley, Mehmet Hakan Kocoglu, Jean A. Yared, Nancy M. Hardy, Aaron P. Rapoport, Djordje Atanackovic
Journal: Blood
Blood (2021) 138 (Supplement 1): 1738.
https://doi.org/10.1182/blood-2021-153949
Published: 2021
Journal Articles

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

Forat Lutfi, Olga Goloubeva, Dong Won Kim, Amer Kowatli, Anton Gryaznov, Philip Margiotta, Lisa R Matsumoto, David Gottlieb, Ali Bukhari, Caroline Dunne, Jennie Y. Law, Seung-Tae Lee, Kathleen Ruehle, Jean A. Yared, Mehmet Hakan Kocoglu, Djordje Atanackovic, Nancy M. Hardy, Wengen Chen, Aaron P. Rapoport, Saurabh Dahiya
Journal: Blood
Blood (2021) 138 (Supplement 1): 3876.
https://doi.org/10.1182/blood-2021-154225
Published: 2021
Journal Articles

The Impact of IDH1c.315C>T Single Nucleotide Polymorphism on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study

Elizabeth Corley, Moaath Mustafa Ali, Hanan Alharthy, Kathryn Kline, Danielle Sewell, Jennie Y. Law, Seung Tae Lee, Sandrine Niyongere, Vu H. Duong, Maria R. Baer, Ashkan Emadi
Journal: Blood
Blood (2021) 138 (Supplement 1): 4454.
https://doi.org/10.1182/blood-2021-151651
Published: 2021
Journal Articles

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Seung Tae Lee, Antonio Pinto, Habte Yimer, Don Stevens, Wanda Knopinska Posluszny, Merrill Kingman Shum, Sudhir Manda, Merav Leiba, Miguel Canales, Maciej Kaźmierczak, Wojciech Jurczak, Anna Sureda, Xiwen Ma, Kai Li, Kimberly Ingalls, Tara Arriola, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Grzegorz S. Nowakowski
Journal: Blood
Blood (2021) 138 (Supplement 1): 1420.
https://doi.org/10.1182/blood-2021-150025
Published: 2021
Journal Articles

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Dong Won Kim, MD, Forat Lutfi, MD, Facundo Zafforoni, BS, Moaath Mustafa Ali, MD MPH, Ali Bukhari, MD, David Gottlieb, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Nancy M. Hardy, MD, Jean A. Yared, MD, Aaron P. Rapoport, MD, Jennie Y. Law, MD, Saurabh Dahiya, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-141992
Published: 2020
Journal Articles

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Forat Lutfi, MD, Ankit Kansagra, MD, Moaath Mustafa Ali, MD, Ali Bukhari, MD, Jonathan Siglin, BS, Jingsheng Yan, PhD, Santanu Samanta, MD, Noa G. Holtzman, MD, David Gottlieb, MD, Dong Won Kim, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Jean A. Yared, MD, Nancy M. Hardy, MD, Jason Molitoris, MD, Pranshu Mohindra, MD, Aaron P. Rapoport, MD, Saurabh Dahiya, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-141231
Published: 2020
Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Craig J. Thomas, PhD, Michele Ceribelli, PhD, Frances Anne Tosto, MS, Craig A. Portell, MD, Rafic J. Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-141447
Published: 2020